MarketPulse

public offering

88 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pharvaris N.V.

Pharvaris Raises $115M to Advance Rare Disease Pipeline

Pharvaris raises $115M through 3.87M share offering at $29.68 per share to advance oral angioedema treatments; Phase 3 data expected Q3 2026.
PHVSPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

LifeStance Health Facilitates $285M Secondary Offering as Insiders Monetize Stakes

LifeStance Health ($LFST) prices $285M secondary offering of 35M shares at $8.15 each, with company repurchasing 6M shares to offset dilution.
LFSTsecondary offeringpublic offering
BenzingaBenzinga··Na

Cold-Pressed Juice Maker Suja Life Prices IPO at $21, Eyes $173.6M Raise

Suja Life prices IPO at $21 per share, raising ~$173.6M to fund debt repayment and parent acquisition. Trading begins May 7 on Nasdaq under ticker $SUJA.
JEFIPOdebt repayment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Avalo Therapeutics Raises $375M to Advance Hidradenitis Suppurativa Treatment

Avalo Therapeutics prices $375M offering of 19.73M shares at $17.75 each to fund Phase 3 development of hidradenitis suppurativa treatment abdakibart, closing May 7, 2026.
AVTXPhase 3 clinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Brazil Potash Raises $63.3M to Accelerate Amazon Potash Mining Project

Brazil Potash ($GRO) closes $63.3M offering to fund Amazon potash development, raising capital through share issuance and warrants for project advancement.
GROwarrantspublic offering
BenzingaBenzinga··Na

Hemab Therapeutics Prices $346.7M IPO as Blood Disorder Biotech Debuts on Nasdaq

Hemab Therapeutics raised $346.7M in upsized IPO, pricing 19.3M shares at $18 with full underwriter exercise.
COAGIPOclinical-stage
BenzingaBenzinga··Sweta Killa

Seaport Therapeutics Eyes Nasdaq Debut With $255M IPO, Signaling Biotech Sector Momentum

Seaport Therapeutics raised $255 million through IPO priced at $18/share, beginning Nasdaq trading Friday as ticker $SPTX, amid growing biotech IPO momentum.
SFTBYAVEXXEIPObiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Senseonics Raises $80M to Fund Eversense 365 Launch and Pipeline Expansion

Senseonics raises $80M through common stock and pre-funded warrant offering to fund Eversense 365 launch and pipeline development, closing May 4, 2026.
SENSpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Rein Therapeutics Raises $50M via IPO to Fund Pulmonary Fibrosis Trial

Rein Therapeutics prices $50M stock offering at $1.00 per share to fund LTI-03 Phase 2 trial for idiopathic pulmonary fibrosis, with cash runway extended through 2028.
RNTXclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Intellia Therapeutics Raises $180M in Stock Offering to Fuel CRISPR Pipeline

Intellia Therapeutics raises $180M via stock offering at $10.75/share to advance CRISPR gene-editing therapies, with lead underwriters Jefferies, Goldman Sachs, Citigroup.
REGNNTLApublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Syntec Optics Raises $20M via Public Offering to Fund Strategic Growth

Syntec Optics prices $20M public offering of 2.86M shares at $7.00 each to fund acquisitions, capex, and debt reduction, closing April 30, 2026.
OPTXOPTXWdefense technologypublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oruka Therapeutics Raises $700M in Upsized Public Offering at $72.50 Per Share

Oruka Therapeutics prices 9.66M shares at $72.50 in upsized offering, raising $700.4M with potential additional proceeds from underwriter overallotment option.
ORKAmonoclonal antibodyclinical-stage
BenzingaBenzinga··Globe Newswire

Auddia Raises $12M in Public Offering to Fuel Growth Initiatives

Auddia raises $12M in public offering, selling 5.08M shares at $2.36 per share. Capital designated for working capital and corporate initiatives.
AUUDwarrantspublic offering
BenzingaBenzinga··Not Specified

Oruka Therapeutics Plans $500M Capital Raise via Public Offering

Oruka Therapeutics plans $500M public offering plus $75M underwriter option to fund monoclonal antibody pipeline for psoriasis and inflammatory conditions.
ORKAmonoclonal antibodypublic offering
BenzingaBenzinga··Altimmune Inc

Altimmune Raises $225M in Oversubscribed Offering to Fuel Phase 3 MASH Trial

Altimmune closed a $225M oversubscribed public offering led by Deep Track Capital. Proceeds will fund Phase 3 MASH trial initiation in H2 2026 and operational runway through data readout.
ALTfinancingclinical trial
The Motley FoolThe Motley Fool··Ryan Vanzo

SpaceX IPO Set for 2026: What $1.75T Valuation Means for Investors

SpaceX targets 2026 IPO at $1-1.75T valuation, raising $50-75B with 30% retail allocation. Investors should expect capital reallocation to other Musk companies.
TSLAvaluationcapital allocation
BenzingaBenzinga··Globe Newswire

Auddia Taps Capital Markets with $12M Offering Ahead of 2026 Close

Auddia priced $12M public offering at $2.36/share, consisting of 5.1M shares and warrants, closing April 2026.
AUUDwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Altimmune Raises $225M in Oversubscribed Offering to Fund MASH Trial

Altimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each.
ALTwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Univest Securities, Llc

Fitness Champs Raises $5M via Public Offering to Fund Asian Expansion

Univest Securities closed $5M public offering for $FCHL, an aquatic sports education provider in Singapore, pricing 3.2M units at $1.55 each.
FCHLpublic offeringcapital raising
BenzingaBenzinga··Adam Eckert

AXT Stock Tumbles 6.5% After Announcing Equity Offering for Capacity Expansion

$AXT shares dip 6.5% after announcing equity offering to expand indium phosphide substrate capacity despite posting 381% year-to-date gains.
AXTIstock declinepublic offering